Developer docs
API playgroundTry for free, no card

Search company profiles

Nanodropper

Full company profile

uuid0000t31

Namestring
Nanodropper
Legal namestring
Nanodropper, Inc.
Websiteurl
nanodropper.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Nanodropper is a privately held US medical device company (Delaware-incorporated) that designs, manufactures, and distributes a microvolume eyedrop delivery adaptor. The core product is an FDA-listed sterile Class I medical device that twists onto standard eyedrop bottles (in Size 14 and Size 15 variants covering the vast majority of US bottles) to reduce dispensed drop volume from the conventional 30-50 μL down to 7-10 μL — a level aligned with the human eye's accommodation capacity and decades of clinical research establishing that smaller drops are equally effective. The company sells the device through three primary channels: direct-to-consumer e-commerce (nanodropper.com), Amazon marketplace (featured on Amazon Buy It Now), and wholesale accounts for eye care professionals, supported by a partner clinic network of 3,000+ clinics across all 50 states. Pricing is positioned around a one-time per-bottle unit purchase with a 20% bulk discount for 4+ units, FSA/HSA eligibility, and a 14-day risk-free trial, with the marketing message centered on extending medication bottle life by up to 3x and reducing prescription costs for patients on expensive branded glaucoma, dry eye, cataract recovery, and pediatric myopia drops.

The company was founded in 2017 by Dr. Allisa Song and operates with a small team (11-50 employees) headquartered in Rochester, Minnesota. Clinical evidence is a central pillar of the business: a peer-reviewed randomized crossover trial published in the Journal of Cataract & Refractive Surgery demonstrated superior IOP reduction (1.6 mm Hg vs 0.13 mm Hg), 80% reduction in premature bottle exhaustion, and 62% vs 83% adverse-effect rates versus conventional drops, with additional work published in Ophthalmology. Beyond the core adaptor, Nanodropper launched the Eye Drop Score patient self-assessment quiz in March 2026, and in January 2026 announced a consolidation with Bedo Solutions and Viseon Labs under a new corporate identity called Mu Medical — a medtech platform play extending into drug delivery, home monitoring, and AI-driven clinical intelligence across four product verticals.

Nanodropper's commercial model combines product-led growth with B2B professional sales and emerging value-based payer channels. Consumer revenue comes from unit device sales online and on Amazon; professional revenue comes from wholesale ordering and free sample programs for optometrists, ophthalmologists, and clinics using the device both in-office (diagnostic drops, dilating drops) and for patient dispensing. In April 2026, the company entered a strategic pharmacy benefit channel via the MediSplit program with MedOne PBM, embedding the device into a value-based benefit structure that has demonstrated 36% prescription cost reduction and 100% adherence among participants. The company has raised approximately $1.9M in disclosed funding (2020 SBIR grant, 2021 seed, 2023 non-dilutive grant), was named a 2025 MN Cup Grand Prize winner, and is transitioning toward the broader Mu Medical platform.

Short descriptiontext

Nanodropper is a US medical device company that sells an FDA-listed microvolume eyedrop bottle adaptor reducing drop size from 30-50 μL to 7-10 μL, sold D2C online, on Amazon, and through 3,000+ partner eye care clinics across all 50 states, serving glaucoma, dry eye, and post-surgical patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRochester, United States
HQ citystring
Rochester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
eye drop adapters, ophthalmic medical devices, precision drug delivery, microvolume dosing, glaucoma medication savings
Industry2 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMALALAG
Dropper Systems (Droppers, Pipettes, Teats)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Nanodropper Device Sales
TypeOne Time License
Description

One-time sale of the FDA-listed sterile microvolume eyedrop delivery device. The adaptor is designed for single-bottle use and extends the life of medication bottles by up to 3x, creating cost savings for patients. Sold directly via e-commerce, Amazon, and wholesale to eye care professionals.

nanodropper.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Single unit purchase with bulk discount available
ModelUnit PricingBilling cadencePay-as-you-go
Notes

20% discount applied automatically when ordering 4 or more Nanodroppers. Device is FSA/HSA eligible. 14-day risk-free trial with return policy.

nanodropper.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nanodropper designs, manufactures, and sells an FDA-listed sterile Class I medical device adaptor that twists onto standard eye drop bottles to deliver microvolume doses (7–10 μL) instead of conventional 30–50 μL drops, extending medication bottle life up to 3x and reducing waste and side effects. The company distributes through a direct-to-consumer e-commerce site, Amazon, professional wholesale, and a partner clinic network, and complements the hardware with the Eye Drop Score self-assessment tool for patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Reduces intraocular pressure by 1.6 mm Hg vs 0.13 mm Hg with conventional drops
+6 more records
Product overview1 text field

Nanodropper offers a portfolio of precision eye drop delivery devices centered on its core FDA-listed microvolume adaptor product. The flagship Nanodropper Adaptor (available in Size 15 and Size 14 variants to fit different bottle sizes) is a sterile Class I medical device that twists onto standard eye drop bottles to deliver smaller, more efficient drops, extending medication life by up to 3x. Complementing the hardware product is the Eye Drop Score, a patient-facing self-assessment tool that helps users evaluate their eye drop routine efficiency and share results with healthcare providers. The company has announced plans to expand into a broader precision eyecare platform under the Mu Medical brand, integrating hardware, home monitoring, and clinical intelligence.

Product and service2 records
1Nanodropper Adaptor
CategoryOphthalmic medical device
Description

FDA-listed sterile Class I medical device adaptor that twists onto standard eye drop bottles and delivers microvolume doses (7–10 μL) instead of conventional 30–50 μL drops. Available in Size 15 (fits the vast majority of standard eye drop bottles) and Size 14 (covers an additional 7% of bottles with 14mm neck measurements). Sold to individual patients and wholesale to eye care professionals; extends medication bottle life up to 3x, reduces waste and side effects, and is FSA/HSA eligible.

2Eye Drop Score
CategoryPatient self-assessment tool
Description

A first-of-its-kind self-check quiz that helps patients on glaucoma, chronic dry eye, or post-operative eye drops assess the efficiency of their treatment routine. Generates downloadable personalized results that patients can share with their eye care provider to support conversations about cost, waste, and adherence.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

MedOne and Nanodropper partnership on the MediSplit program, a value-based pharmacy benefit initiative pairing Nanodropper's precision eye drop delivery device with MedOne's PBM network. Early results show 36% reduction in prescription drug costs, 100% of participants never missed doses due to running out or side effects, and up to $160 PMPM savings. Demonstrates integration of medical devices into pharmacy benefit models.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Bedo Solutions joined Nanodropper's precision eyecare platform under new corporate identity Mu Medical. The consolidation integrates hardware and software assets to create a comprehensive medtech ecosystem covering drug delivery, home monitoring, and AI-driven clinical intelligence across four product verticals. Formal debut during J.P. Morgan Healthcare Conference week January 2026.

3Viseon Labs
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Viseon Labs joined Nanodropper's precision eyecare platform under new corporate identity Mu Medical. The consolidation integrates hardware and software assets to create a comprehensive medtech ecosystem covering drug delivery, home monitoring, and AI-driven clinical intelligence across four product verticals. Formal debut during J.P. Morgan Healthcare Conference week January 2026.

prnewswire.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Major ophthalmic pharmaceutical and device company producing prescription and OTC eye drops. Comparable as both a potential channel partner and potential competitive threat if redesigning bottles.

TypeDirect peer
Description

Medical device company specializing in drug delivery aids including eye drop applicators (OptiCare) and ophthalmic accessories. Closely comparable to Nanodropper in offering patient-facing devices that improve eye drop administration and adherence.

TypeBroad incumbent
Description

Large medical technology company with a pharmaceutical systems segment producing drug delivery devices, ophthalmic devices, and injection systems. Broadly comparable as an incumbent with adjacent ocular and drug delivery capabilities.

TypeBroad incumbent
Description

Global drug delivery device manufacturer producing ophthalmic dropper bottles, pumps, and dispensing systems for pharmaceutical companies. Directly relevant as a supplier of comparable dropper technology to the pharma industry that Nanodropper targets as end users.

TypeBroad incumbent
Description

Medical device and pharmaceutical company producing ophthalmic surgical products and drug delivery solutions. Comparable as an established medtech player overlapping with Nanodropper's drug delivery space.

TypeBroad incumbent
Description

Global manufacturer of pharmaceutical packaging including glass dropper bottles and plastic ophthalmic containers. Comparable as a primary packaging supplier whose bottle designs influence the market Nanodropper addresses.

TypeBroad incumbent
Description

Major dispensing solutions provider offering ophthalmic dropper tips, pumps, and closures for pharmaceutical and personal care markets. Comparable as an incumbent supplier of dropper components Nanodropper's adaptor sits alongside.

TypeDirect peer
Description

Manufacturer of precision ophthalmic dropper bottles and dispensing systems producing calibrated micro-doses for pharmaceutical applications. Highly comparable as a competing supplier of microvolume drop delivery technology.

9EyeGate Pharmaceuticals
TypeEmerging player
Description

Specialty pharmaceutical and drug delivery company developing ocular drug delivery platforms. Comparable as a smaller player focused specifically on improving ophthalmic drug administration.

TypeOthers
Description

Major ophthalmic pharmaceutical manufacturer producing branded eye drops including Restasis and Lumigan. Comparable as a key upstream supplier whose bottle designs Nanodropper's adaptor is designed to retrofit.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanodropper

Ophthalmic Medical Devicesnanodropper.com

Nanodropper is a US medical device company that sells an FDA-listed microvolume eyedrop bottle adaptor reducing drop size from 30-50 μL to 7-10 μL, sold D2C online, on Amazon, and through 3,000+ partner eye care clinics across all 50 states, serving glaucoma, dry eye, and post-surgical patients.

What Nanodropper does

Nanodropper is a privately held US medical device company (Delaware-incorporated) that designs, manufactures, and distributes a microvolume eyedrop delivery adaptor. The core product is an FDA-listed sterile Class I medical device that twists onto standard eyedrop bottles (in Size 14 and Size 15 variants covering the vast majority of US bottles) to reduce dispensed drop volume from the conventional 30-50 μL down to 7-10 μL — a level aligned with the human eye's accommodation capacity and decades of clinical research establishing that smaller drops are equally effective. The company sells the device through three primary channels: direct-to-consumer e-commerce (nanodropper.com), Amazon marketplace (featured on Amazon Buy It Now), and wholesale accounts for eye care professionals, supported by a partner clinic network of 3,000+ clinics across all 50 states. Pricing is positioned around a one-time per-bottle unit purchase with a 20% bulk discount for 4+ units, FSA/HSA eligibility, and a 14-day risk-free trial, with the marketing message centered on extending medication bottle life by up to 3x and reducing prescription costs for patients on expensive branded glaucoma, dry eye, cataract recovery, and pediatric myopia drops.

The company was founded in 2017 by Dr. Allisa Song and operates with a small team (11-50 employees) headquartered in Rochester, Minnesota. Clinical evidence is a central pillar of the business: a peer-reviewed randomized crossover trial published in the Journal of Cataract & Refractive Surgery demonstrated superior IOP reduction (1.6 mm Hg vs 0.13 mm Hg), 80% reduction in premature bottle exhaustion, and 62% vs 83% adverse-effect rates versus conventional drops, with additional work published in Ophthalmology. Beyond the core adaptor, Nanodropper launched the Eye Drop Score patient self-assessment quiz in March 2026, and in January 2026 announced a consolidation with Bedo Solutions and Viseon Labs under a new corporate identity called Mu Medical — a medtech platform play extending into drug delivery, home monitoring, and AI-driven clinical intelligence across four product verticals.

Nanodropper's commercial model combines product-led growth with B2B professional sales and emerging value-based payer channels. Consumer revenue comes from unit device sales online and on Amazon; professional revenue comes from wholesale ordering and free sample programs for optometrists, ophthalmologists, and clinics using the device both in-office (diagnostic drops, dilating drops) and for patient dispensing. In April 2026, the company entered a strategic pharmacy benefit channel via the MediSplit program with MedOne PBM, embedding the device into a value-based benefit structure that has demonstrated 36% prescription cost reduction and 100% adherence among participants. The company has raised approximately $1.9M in disclosed funding (2020 SBIR grant, 2021 seed, 2023 non-dilutive grant), was named a 2025 MN Cup Grand Prize winner, and is transitioning toward the broader Mu Medical platform.

Nanodropper firmographics

Firmographics
Name
Nanodropper
Legal name
Nanodropper, Inc.
Website
https://nanodropper.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Nanodropper is a US medical device company that sells an FDA-listed microvolume eyedrop bottle adaptor reducing drop size from 30-50 μL to 7-10 μL, sold D2C online, on Amazon, and through 3,000+ partner eye care clinics across all 50 states, serving glaucoma, dry eye, and post-surgical patients.
Ownership category
akta.pro rank

Nanodropper industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Ophthalmic Goods Manufacturing (339115)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMALALAG
Dropper Systems (Droppers, Pipettes, Teats)

Keywords

  • Eye drop adapters
  • Ophthalmic medical devices
  • Precision drug delivery
  • Microvolume dosing
  • Glaucoma medication savings

Where Nanodropper is headquartered

Location

Headquarters

HQ city
Rochester
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nanodropper business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Nanodropper Device Sales: One-time sale of the FDA-listed sterile microvolume eyedrop delivery device. The adaptor is designed for single-bottle use and extends the life of medication bottles by up to 3x, creating cost savings for patients. Sold directly via e-commerce, Amazon, and wholesale to eye care professionals.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSingle unit purchase with bulk discount available

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Nanodropper product offering

Product offering

Core offering

Nanodropper designs, manufactures, and sells an FDA-listed sterile Class I medical device adaptor that twists onto standard eye drop bottles to deliver microvolume doses (7–10 μL) instead of conventional 30–50 μL drops, extending medication bottle life up to 3x and reducing waste and side effects. The company distributes through a direct-to-consumer e-commerce site, Amazon, professional wholesale, and a partner clinic network, and complements the hardware with the Eye Drop Score self-assessment tool for patients.

Product overview

Nanodropper offers a portfolio of precision eye drop delivery devices centered on its core FDA-listed microvolume adaptor product. The flagship Nanodropper Adaptor (available in Size 15 and Size 14 variants to fit different bottle sizes) is a sterile Class I medical device that twists onto standard eye drop bottles to deliver smaller, more efficient drops, extending medication life by up to 3x. Complementing the hardware product is the Eye Drop Score, a patient-facing self-assessment tool that helps users evaluate their eye drop routine efficiency and share results with healthcare providers. The company has announced plans to expand into a broader precision eyecare platform under the Mu Medical brand, integrating hardware, home monitoring, and clinical intelligence.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nanodropper Adaptor FDA-listed sterile Class I medical device adaptor that twists onto standard eye drop bottles and delivers microvolume doses (7–10 μL) instead of conventional 30–50 μL drops. Available in Size 15 (fits the vast majority of standard eye drop bottles) and Size 14 (covers an additional 7% of bottles with 14mm neck measurements). Sold to individual patients and wholesale to eye care professionals; extends medication bottle life up to 3x, reduces waste and side effects, and is FSA/HSA eligible.
  • Eye Drop Score A first-of-its-kind self-check quiz that helps patients on glaucoma, chronic dry eye, or post-operative eye drops assess the efficiency of their treatment routine. Generates downloadable personalized results that patients can share with their eye care provider to support conversations about cost, waste, and adherence.

Quantifiable outcome

  • Reduces intraocular pressure by 1.6 mm Hg vs 0.13 mm Hg with conventional drops
  • +6 more outcomes

Companies that use Nanodropper

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Nanodropper technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Nanodropper partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • MedOnecoreStrategic or Co-development Partner · 2 April 2026MedOne and Nanodropper partnership on the MediSplit program, a value-based pharmacy benefit initiative pairing Nanodropper's precision eye drop delivery device with MedOne's PBM network. Early results show 36% reduction in prescription drug costs, 100% of participants never missed doses due to running out or side effects, and up to $160 PMPM savings. Demonstrates integration of medical devices into pharmacy benefit models.
  • Bedo SolutionsflagshipStrategic or Co-development Partner · 9 January 2026Bedo Solutions joined Nanodropper's precision eyecare platform under new corporate identity Mu Medical. The consolidation integrates hardware and software assets to create a comprehensive medtech ecosystem covering drug delivery, home monitoring, and AI-driven clinical intelligence across four product verticals. Formal debut during J.P. Morgan Healthcare Conference week January 2026.
  • Viseon LabsflagshipStrategic or Co-development Partner · 9 January 2026Viseon Labs joined Nanodropper's precision eyecare platform under new corporate identity Mu Medical. The consolidation integrates hardware and software assets to create a comprehensive medtech ecosystem covering drug delivery, home monitoring, and AI-driven clinical intelligence across four product verticals. Formal debut during J.P. Morgan Healthcare Conference week January 2026.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Nanodropper competitors and assessment

Company assessment

Others

  • Bausch + Lomb: Major ophthalmic pharmaceutical and device company producing prescription and OTC eye drops. Comparable as both a potential channel partner and potential competitive threat if redesigning bottles.
  • Allergan/AbbVie Aesthetics: Major ophthalmic pharmaceutical manufacturer producing branded eye drops including Restasis and Lumigan. Comparable as a key upstream supplier whose bottle designs Nanodropper's adaptor is designed to retrofit.

Direct peers

  • Owen Mumford: Medical device company specializing in drug delivery aids including eye drop applicators (OptiCare) and ophthalmic accessories. Closely comparable to Nanodropper in offering patient-facing devices that improve eye drop administration and adherence.
  • Aero Pump: Manufacturer of precision ophthalmic dropper bottles and dispensing systems producing calibrated micro-doses for pharmaceutical applications. Highly comparable as a competing supplier of microvolume drop delivery technology.

Broad incumbents

  • Becton Dickinson (BD): Large medical technology company with a pharmaceutical systems segment producing drug delivery devices, ophthalmic devices, and injection systems. Broadly comparable as an incumbent with adjacent ocular and drug delivery capabilities.
  • Aptar Pharma: Global drug delivery device manufacturer producing ophthalmic dropper bottles, pumps, and dispensing systems for pharmaceutical companies. Directly relevant as a supplier of comparable dropper technology to the pharma industry that Nanodropper targets as end users.
  • B. Braun: Medical device and pharmaceutical company producing ophthalmic surgical products and drug delivery solutions. Comparable as an established medtech player overlapping with Nanodropper's drug delivery space.
  • Gerresheimer: Global manufacturer of pharmaceutical packaging including glass dropper bottles and plastic ophthalmic containers. Comparable as a primary packaging supplier whose bottle designs influence the market Nanodropper addresses.
  • Silgan Dispensing: Major dispensing solutions provider offering ophthalmic dropper tips, pumps, and closures for pharmaceutical and personal care markets. Comparable as an incumbent supplier of dropper components Nanodropper's adaptor sits alongside.

Emerging players

  • EyeGate Pharmaceuticals: Specialty pharmaceutical and drug delivery company developing ocular drug delivery platforms. Comparable as a smaller player focused specifically on improving ophthalmic drug administration.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Nanodropper social profiles

Digital presence

Nanodropper compliance and trust

Trust signal

Compliance2 records

Nanodropper financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanodropper leadership team

Management profile

Number of profiles

Profiles4 records

Nanodropper funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanodropper M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanodropper

What does Nanodropper do?

Nanodropper designs, manufactures, and sells an FDA-listed sterile Class I medical device adaptor that twists onto standard eye drop bottles to deliver microvolume doses (7–10 μL) instead of conventional 30–50 μL drops, extending medication bottle life up to 3x and reducing waste and side effects. The company distributes through a direct-to-consumer e-commerce site, Amazon, professional wholesale, and a partner clinic network, and complements the hardware with the Eye Drop Score self-assessment tool for patients.

Is Nanodropper a public or private company?

Nanodropper is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nanodropper founded?

Nanodropper was founded in 2017. It employs 1 to 10 people.

Where is Nanodropper based?

Nanodropper is headquartered in Rochester, United States, in the North America region.

How does Nanodropper make money?

One revenue line is on record: nanodropper Device Sales.

Who are Nanodropper's main competitors?

Others on record are Bausch + Lomb and Allergan/AbbVie Aesthetics. Direct peers are Owen Mumford and Aero Pump. Broad incumbents are Becton Dickinson (BD), Aptar Pharma, B. Braun, Gerresheimer and Silgan Dispensing. EyeGate Pharmaceuticals is listed as an emerging player.

Does Nanodropper have an API?

No public API is recorded for Nanodropper.

What industry is Nanodropper in?

Nanodropper's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of IMALALAG, Dropper Systems (Droppers, Pipettes, Teats). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMedOne and Nanodropper Announce Early Success of MediSplit Program, Demonstrating Reduced Cost, Improved Adherence, and Reduced Side EffectsMedOne and Nanodropper announced early positive results from the MediSplit program, which aims to improve medication adherence and reduce side effects for patients using prescription eye drops. The program demonstrated significant improvements in adherence, side effect reduction, and cost savings, with 36% of participants experiencing lower costs and 36% reporting fewer side effects.MorningstarMedOne and Nanodropper Announce Early Success of MediSplit Program, Demonstrating Reduced Cost, Improved Adherence, and Reduced Side EffectsMedOne and Nanodropper announced early results from their MediSplit program, a value-based clinical care initiative providing eligible MedOne members with complimentary Nanodropper precision eye drop devices. The program demonstrated 100% adherence rates (up from 40%), with participants achieving 36% reduction in prescription drug costs, average savings of $105 per claim, and up to $160 PMPM savings per medication. These results highlight the integration of medical devices into pharmacy benefit strategies as a pathway for improved patient outcomes and cost efficiencies for payers and employers.BioSpaceMedOne and Nanodropper Announce Early Success of MediSplit Program, Demonstrating Reduced Cost, Improved Adherence, and Reduced Side EffectsMedOne and Nanodropper announced early results from their MediSplit program, a value-based pharmacy benefit initiative pairing Nanodropper's precision eye drop delivery device with MedOne's PBM network, showing 100% of participants never missed doses due to running out or side effects (improving from 40% and 20% baselines respectively), with 36% reporting reduced side effect prevalence and 53% reporting reduced severity. The program generated 36% reduction in prescription drug costs, averaging $105 savings per claim and up to $160 PMPM savings per medication for patients whose eye drop medications cost health plans up to $399 monthly.BioSpaceNew Clinical Study Shows Nanodropper Microvolume Delivery Device Provides Superior Efficacy, Fewer Side Effects, and Dramatically Reduces Early Eyedrop Bottle ExhaustionNanodropper announced results from a prospective, examiner-masked, randomized crossover trial published in the Journal of Cataract & Refractive Surgery, demonstrating that its microvolume eyedrop delivery adaptor achieved superior intraocular pressure reduction (1.6 mm Hg vs 0.13 mm Hg with conventional drops) in patients with glaucoma or ocular hypertension. The study also found an 80% reduction in premature bottle exhaustion and fewer reported adverse effects (62% vs 83%) compared to standard eyedrop delivery over a 12-week crossover period.PR NewswireNew Clinical Study Shows Nanodropper Microvolume Delivery Device Provides Superior Efficacy, Fewer Side Effects, and Dramatically Reduces Early Eyedrop Bottle ExhaustionNanodropper announced results from a randomized clinical trial published in the Journal of Cataract & Refractive Surgery, demonstrating that its microvolume eyedrop adaptor achieved superior intraocular pressure reduction (1.6 mm Hg vs 0.13 mm Hg from baseline) compared to conventional drops in patients with glaucoma or ocular hypertension. The study found an 80% reduction in premature bottle exhaustion and 21% fewer reported adverse effects with the Nanodropper device versus conventional drops. Researchers concluded that microdrop delivery may enhance medication adherence and long-term glaucoma management by reducing overflow, medication waste, and systemic exposure.MorningstarNew Clinical Study Shows Nanodropper Microvolume Delivery Device Provides Superior Efficacy, Fewer Side Effects, and Dramatically Reduces Early Eyedrop Bottle ExhaustionA randomized clinical trial published in the Journal of Cataract & Refractive Surgery found that the Nanodropper microvolume eyedrop adaptor achieved superior intraocular pressure reduction (1.6 mm Hg vs 0.13 mm Hg) and fewer adverse effects compared with conventional eyedrops in patients with glaucoma or ocular hypertension. The study also found that 80% of patients using conventional drops experienced early bottle exhaustion compared to only 17% with the Nanodropper device. Authors concluded that microdrop delivery technology may enhance medication adherence and long-term glaucoma management.PR NewswireNanodropper Launches the First-Ever "Eye Drop Score" to Help Patients Improve Their Eye Drop RoutineNanodropper Inc. announced the launch of the Eye Drop Score, a first-of-its-kind self-check quiz designed to help patients using prescription or over-the-counter eye medications evaluate how efficiently their eye drop routine is working. The quiz addresses common challenges such as running out of drops early, medication costs, and side effects or discomfort, providing personalized results that patients can share with their eye care providers. The tool is intended to help patients have more informed conversations about their treatment plans for conditions like glaucoma, chronic dry eye, or post-operative recovery.MorningstarNanodropper Launches the First-Ever "Eye Drop Score" to Help Patients Improve Their Eye Drop RoutineNanodropper Inc., a medical technology company based in Rochester, Minnesota, announced on March 13, 2026 the launch of the Eye Drop Score, a first-of-its-kind self-check quiz designed to help patients using prescription or over-the-counter eye drops for conditions such as glaucoma, chronic dry eye, or post-operative recovery assess how efficiently their treatment routine is working. The quiz provides personalized results that patients can download and share with their eye care provider to facilitate more informed conversations about their treatment plan. The tool aims to help patients identify challenges related to medication cost, drop waste, or comfort that may be making their treatment more difficult than necessary.Eyes On EyecareNanodropper now operating as Mu Medical, a precision eyecare platformNanodropper has rebranded as Mu Medical and consolidated with Bedo Solutions and Viseon Labs to form a precision eyecare platform, debuting this week at the J.P. Morgan Healthcare Conference. The merged entity will integrate assets from all three physician-founded companies into four product categories focusing on consumer devices, primary packaging, monitoring, and AI therapeutics. This strategic move aims to transition from a single-product manufacturer to a broader medtech ecosystem addressing personalized eye care.Eyewire+Nanodropper Now Operating as Mu Medical Under New Consolidation PlanNanodropper announced a consolidation plan to merge with Bedo Solutions and Viseon Labs under the new corporate identity Mu Medical. The combined entity aims to create a broader medtech ecosystem spanning hardware, software, and AI-driven therapeutics for ocular care. Financial terms of the deal were not disclosed.